Target intelligence / Profile preview

Mitogen-activated protein kinase 8 (JNK1) (JNK1)

Target
JNK1
Molecular classification
Enzyme, Kinase, Serine/threonine-protein kinase, Mitogen-activated protein kinase
01

Overview

Mitogen-activated protein kinase 8 (JNK1) is a serine/threonine-protein kinase belonging to the c-Jun N-terminal kinase (JNK) subfamily of the mitogen-activated protein kinase (MAPK) superfamily. It is activated by dual-specificity kinases MAP2K4/MKK4 and MAP2K7/MKK7 in response to environmental stress, pro-inflammatory cytokines, and DNA damage. Upon activation, JNK1 phosphorylates various transcription factors, most notably c-Jun, which regulates the activity of the AP-1 transcription factor complex to control cell proliferation, differentiation, and apoptosis. Dysregulation of JNK1 signaling is heavily implicated in the pathogenesis of chronic inflammatory diseases, metabolic disorders like insulin resistance and type 2 diabetes, fibrosis, and various cancers. Consequently, JNK1 has emerged as a significant therapeutic target, with several small-molecule inhibitors, such as BMS-986360 and CC-930, developed to block its kinase activity. However, because JNK1 is ubiquitously expressed and plays critical roles in normal physiological processes, achieving high selectivity and avoiding systemic toxicity remain major challenges in drug development.

Other names
c-Jun N-terminal kinase 1Stress-activated protein kinase JNK1Stress-activated protein kinase 1cSAPK1CPRKM8SAPK1JNK-46MAPK8
02

Mechanism of action

ATP-competitive inhibition of serine/threonine-protein kinase activity, covalent inhibition of the conserved cysteine residue in the active site, or peptide-mediated inhibition of substrate binding.

03

Biological functions

Signal transductionApoptosisCell proliferationCell differentiationImmune responseAutophagyTranscription regulation
04

Disease associations

CancerInflammationNeurodegenerative diseaseCardiovascular diseaseAutoimmune diseaseMetabolic diseaseFibrosis
05

Safety considerations

Off-target kinase inhibitionSystemic toxicity due to ubiquitous expression of JNK1Impairment of physiological immune responsesPotential liver toxicityDisruption of normal cell survival and tissue repair pathways
06

Interacting drugs

5 more in the full profile.

07

Biomarkers

Phosphorylated c-Jun (p-c-Jun)Phosphorylated JNK (p-JNK)AP-1 transcriptional activityPhosphorylated ATF2Phosphorylated tau

Beyond the preview

Go deeper on Mitogen-activated protein kinase 8 (JNK1) (JNK1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mitogen-activated protein kinase 8 (JNK1) (JNK1).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call